Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. CanSino Biologics Inc.
  6. News
  7. Summary
    6185   CNE100003F01

CANSINO BIOLOGICS INC.

(6185)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Coronavirus Pandemic: Chinese developer shares efficacy of inhaled vaccines

09/06/2021 | 09:52pm EDT
Coronavirus Pandemic: Chinese developer shares efficacy of inhaled vaccines
2021-09

More than 2.08 billion doses of COVID-19 vaccines had been administered in China as of Thursday. For months, trials have been underway in China for an inhaled vaccine against COVID-19. CanSinoBIO is also the maker behind China's first single-dose jab. CGTN's Ning Hong pays a visit to its researchers in the port city of Tianjin.

One deep breath can help provide protection against COVID-19. This may well be the reality, as Chinese developers work on an inhaled vaccine. They've said that the first phase of clinical trials has shown promising results.

SI WEIXUE Deputy Director, CanSino Vaccine R&D Department 'We are very confident and excited. Whether it's two doses through an inhaled vaccine or an intramuscular injection, the inhaled vaccine can be used as a booster to strengthen antibody immunity, such as Immunoglobulin G. Antibody levels have shown to be better than in the one-shot vaccine we previously approved. The inhaled vaccine can also produce high levels of cellular immunity.'

Researchers say, unlike most COVID jabs available, the inhaled vaccine can stimulate a better mucosal immune response in a person's lower respiratory tract, which experts say is the main target of SARS-CoV-2, or the virus that causes COVID-19.

A study published in July in the Lancet Infectious Diseases journal says no serious adverse events were noted within 56 days after the first inhaled vaccine.

For better protection, researchers suggest two doses or a combination of an inhaled vaccine with an intramuscular jab.

SI WEIXUE Deputy Director, CanSino Vaccine R&D Department 'Based on the results of our clinical trials, through inhalation only, one dose provides basic immunity while an additional dose heightens protective effect. Using different immunization methods, clinical trials show better protection if the first dose is an intramuscular injection. The inhaled dose boosts the efficacy of the injection.'

China approved CanSino's Convidecia in February - a one-shot vaccine against COVID-19.

Researchers say they are now working on the dosing equipment before the inhaled vaccines hit the market.

SI WEIXUE Deputy Director, CanSino Vaccine R&D Department 'We have designed a device that can facilitate faster and more convenient drug delivery for doctors and vaccinators. The equipment we developed can accurately administer drugs.'

A new production line is now fully operational inside the CanSino plant in Tianjin. This comes as the development of new inhaled vaccine is speeding up.

NING HONG Tianjin 'The development of an inhalable vaccine provides an alternative option for the CDC. And it's growing to become a vital factor that will speed up the global efforts to control COVID-19. Ning Hong. CGTN, Tianjin.'

Disclaimer

Cansino Biologics Inc. published this content on 06 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 September 2021 01:51:01 UTC.


ę Publicnow 2021
All news about CANSINO BIOLOGICS INC.
10/20CANSINO BIOLOGICS : Restricting travel over vaccine type could be discrimination, PAHO war..
RE
10/11CanSino Biologics Inc. Announces Appointment of Jing Wang as an Executive Director
CI
10/09CANSINO BIOLOGICS : GLOBALink | Argentina uses Chinese CanSino COVID-19 vaccine to immuniz..
PU
10/05OCUGEN : Bharat Biotech Enter Supply Deal for COVID-19 Vaccine Candidate; Commercializatio..
MT
09/24CANSINO BIOLOGICS : CanSinoBIO's COVID vaccine, tested at lower dosage, safe for children ..
RE
09/20CANSINO BIOLOGICS INC.(XSSC : 688185) added to S&P Global BMI Index
CI
09/10Cansino Biologics Inc. Announces Executive Changes
CI
09/07CANSINO BIOLOGICS : Indonesia approves J&J, Cansino COVID-19 vaccines for emergency use
RE
09/07SINOVAC BIOTECH : Mixing CanSinoBIO, Sinovac COVID shots induces stronger response than Si..
RE
09/06CORONAVIRUS PANDEMIC : Chinese developer shares efficacy of inhaled vaccines
PU
More news
Analyst Recommendations on CANSINO BIOLOGICS INC.
More recommendations
Financials
Sales 2021 9 984 M 1 564 M 1 564 M
Net income 2021 2 378 M 373 M 373 M
Net cash 2021 5 073 M 795 M 795 M
P/E ratio 2021 8,85x
Yield 2021 0,00%
Capitalization 58 059 M 9 095 M 9 097 M
EV / Sales 2021 5,31x
EV / Sales 2022 1,74x
Nbr of Employees 726
Free-Float 37,1%
Chart CANSINO BIOLOGICS INC.
Duration : Period :
CanSino Biologics Inc. Technical Analysis Chart | 6185 | CNE100003F01 | MarketScreener
Technical analysis trends CANSINO BIOLOGICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 178,15 CNY
Average target price 308,63 CNY
Spread / Average Target 73,2%
EPS Revisions
Managers and Directors
Xue Feng Yu Chairman, Chief Executive Officer & GM
Xi Luo Chief Financial Officer
Jiang Feng Li Chairman-Supervisory Board
Tao Zhu Executive Director, CSO & Deputy General Manager
Jun Qiang Li Senior Director-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CANSINO BIOLOGICS INC.22.95%9 344
CSL LIMITED4.53%100 969
WUXI BIOLOGICS (CAYMAN) INC.16.73%64 238
SAMSUNG BIOLOGICS CO.,LTD.6.42%49 692
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.10.24%40 230